Skip to main content

X4 Pharmaceuticals, Inc

corporate_fare Company Profile

X4 Pharmaceuticals, Inc

XFOR·NASDAQ·Life Sciences·CIK 0001501697

X4 Pharmaceuticals, Inc. is a biopharmaceutical company that researches, develops, and commercializes new treatments for rare immune system diseases. The company's primary product is XOLREMDI, an orally administered small-molecule selective antagonist of the chemokine receptor CXCR4. XOLREMDI is currently in a Phase 3 clinical trial for treating patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. X4 Pharmaceuticals has several licensing agreements for XOLREMDI. It has an agreement with Abbisko Therapeutics Co Ltd. for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, manufacturing, and commercialization of mavorixafor (XOLREMDI) in Europe, Australia, and New Zealand. Additionally, the company has a license agreement with Genzyme Corporation for the CXCR4 receptor, allowing Genzyme to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic, and diagnostic uses. X4 Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

X4 Pharmaceuticals, Inc (NASDAQ:XFOR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for XFOR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for XFOR spans 10-Q, 8-K, DEFA14A, DEF 14A.

Recent high-impact activity:

  • X4 Pharmaceuticals Narrows Q3 Loss to 16c/Share, Cash at $187.7M
  • X4 Posts Narrower Q3 Loss, $187.7M Cash, and Details K2 Loan Covenants
  • X4 Investor Day: 4WARD Enrollment Due Q4 2026, Topline Q1 2028, ~15K-Patient PCN Base Case
  • X4 Pharmaceuticals Secures Up to $150M Debt Facility, Repays Prior Loan
  • X4 Posts Corporate Presentation With Detailed Phase 2 Data Supporting 4WARD Pivotal Trial

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$6.5M
Net Income
-$79.2M
Diluted EPS
-$1.87
Op. Cash Flow
-$85.62M
Free Cash Flow
-$85.62M
Gross Profit
$743K
Operating Income
-$86.88M
Cash & Equivalents
$217.05M
Total Debt
$75M
Debt / Equity
0.40×
Net Margin
-12.18×
Shares Outstanding
90.91M sh
Source: 10-K · filed 2026-03-17 · accession 0001501697-26-000018

Short Interest & Short Volume

10.86 days to cover

FINRA reported short interest of 7,973,579 shares in XFOR as of the October 30, 2026 settlement, a 6.5% increase from the prior period — about 10.9 days to cover at its recent average daily volume. On November 20, 2026, 38.6% of XFOR volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)7,973,579 shares as of October 30, 2026
Change vs prior period▲ 6.5%
Days to cover10.86 at avg daily volume of 734,226
Daily short volume (FINRA facilities)38.6% of 931,025 shares on November 20, 2026
5-day average short volume46.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with X →
$3
52-week range · as of 2026-11-04 $2.43 – $4.83
Market cap
$306.34M
Volume
1.8M (2.4× avg)
3-mo avg 775.3K
Live data · 2026-11-21 07:42 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed XFOR - Latest Insights

XFOR
Nov 04, 2026, 4:15 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $3.24
Real-time Price: $3.00 info
Change: -$0.240 (-7%) info
Market Cap: $306.341M info
XFOR
Nov 04, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.24
Real-time Price: $3.00 info
Change: -$0.240 (-7%) info
Market Cap: $306.341M info
XFOR
Oct 29, 2026, 9:59 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.44
Real-time Price: $3.00 info
Change: -$0.440 (-13%) info
Market Cap: $306.341M info
XFOR
Oct 08, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Updated Oct 8, 5:25 PM ET — The 8-K details the loan terms: $80M first tranche funded, up to $70M second tranche, interest at greater of 8.55% or prime +1.55% plus 1.0…
Price at Filing: $2.81
Real-time Price: $3.00 info
Change: +$0.1899 (+7%) info
Market Cap: $306.341M info
XFOR
Sep 08, 2026, 5:36 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.60
Real-time Price: $3.00 info
Change: -$0.600 (-17%) info
Market Cap: $306.341M info
XFOR
Sep 08, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.12
Real-time Price: $3.00 info
Change: -$1.12 (-27%) info
Market Cap: $306.341M info
XFOR
Sep 08, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.14
Real-time Price: $3.00 info
Change: -$1.14 (-28%) info
Market Cap: $306.341M info
XFOR
Aug 06, 2026, 4:15 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.25
Real-time Price: $3.00 info
Change: -$1.25 (-29%) info
Market Cap: $306.341M info
XFOR
Aug 06, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.25
Real-time Price: $3.00 info
Change: -$1.25 (-29%) info
Market Cap: $306.341M info
XFOR
Jul 01, 2026, 4:13 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.09
Real-time Price: $3.00 info
Change: -$1.09 (-27%) info
Market Cap: $306.341M info
XFOR
May 12, 2026, 4:21 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.34
Real-time Price: $3.00 info
Change: -$1.34 (-31%) info
Market Cap: $306.341M info
XFOR
May 06, 2026, 7:01 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.16
Real-time Price: $3.00 info
Change: -$1.16 (-28%) info
Market Cap: $306.341M info
XFOR
Mar 20, 2026, 8:49 AM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $4.29
Real-time Price: $3.00 info
Change: -$1.29 (-30%) info
Market Cap: $306.341M info
XFOR
Mar 20, 2026, 8:45 AM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $4.29
Real-time Price: $3.00 info
Change: -$1.29 (-30%) info
Market Cap: $306.341M info
XFOR
Mar 17, 2026, 7:15 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $3.70
Real-time Price: $3.00 info
Change: -$0.700 (-19%) info
Market Cap: $306.341M info
XFOR
Mar 17, 2026, 6:59 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $3.56
Real-time Price: $3.00 info
Change: -$0.560 (-16%) info
Market Cap: $306.341M info
XFOR
Feb 27, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $3.21
Real-time Price: $3.00 info
Change: -$0.210 (-7%) info
Market Cap: $306.341M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets